Cargando…
A phase I clinical trial of dose escalation of lobaplatin in combination with fixed-dose docetaxel for the treatment of human solid tumours that had progressed following chemotherapy
In this study, the maximum tolerated dose (MTD) of lobaplatin (LBP) when it was combined with docetaxel (TXT) for the treatment of solid tumours that had progressed following chemotherapy was determined, and toxicities to this regimen were evaluated. A modified Fibonacci method was used for the dose...
Autores principales: | PENG, YU, LIU, YUE-E, REN, XIAO-CAN, CHEN, XUE-JI, SU, HUI-LING, ZONG, JIE, FENG, ZENG-LI, WANG, DONG-YING, LIN, QIANG, GAO, XIAN-SHU |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246893/ https://www.ncbi.nlm.nih.gov/pubmed/25435935 http://dx.doi.org/10.3892/ol.2014.2675 |
Ejemplares similares
-
Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012) -
Dose Escalation of Lobaplatin Concurrent with IMRT for the Treatment of Stage III-IVb NPC: A Phase I Clinical Trial()()
por: Wang, Si-Yang, et al.
Publicado: (2018) -
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study
por: Robert, Francisco, et al.
Publicado: (2009) -
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013) -
Safety, anti-tumour activity, and pharmacokinetics of
fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a
dose-escalation, phase 1 study
por: Mo, Hongnan, et al.
Publicado: (2018)